Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$3.34
▲ $0.05 (+1.5%)
Market data updated: 09/26 01:58 AM
Fundamentals updated: 09/26/2026
News analyzed: 09/26/2026
Market Cap
$1.07B
Day Range
$3.17 - $3.39
52-Week Range
$2.23 - $6.51
Beta
—
Next Earnings
03.11.2026
Support
$3.17
Resistance
$4.40
MNKD is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-37.3% (1Y)
Strengths: 8/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 22.2%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $0.22 vs. price $3.34 (-93.4%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
41
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
63
Value
33
Momentum
13
Risk
46
Sentiment
68
Fundamental
55
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of MannKind Corporation (MNKD) has focused on its upcoming investor presentations at major conferences, including the Cantor Global Healthcare and H.C. Wainwright Global Investment Conferences in September 2026. Analysts have also highlighted the company’s perceived undervaluation—estimating a 48% discount based on its Afrezza insulin product and pipeline potential—while noting weak recent share performance. Additionally, there are reports of a prospectus filing for a potential stock resale by selling shareholders, including warrants, and optimism about diversified revenue growth in the second half of 2026.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about MannKind Corporation. News trend score: 68. Reason: 6 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
39
🎯 Conviction (vs. Emotion)
42
Psychology
45
Fundamentals
55
Technical
13
Valuation
33
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-19%
Market Narrative
52
Fundamental Reality
42
Narrative Gap
+10
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
MNKD’s psychology suggests a blend of overconfidence and anchoring, with euphoria lurking. The extreme valuation gap (+1831% vs. DCF) and momentum decoupling from fundamentals fuel overconfidence, while the near-resistance anchor may limit upside. The narrative-reality gap (27) hints at detached expectations, but the lack of panic or herding signals suggests traders remain cautiously optimistic. The key question: will momentum sustain despite valuation extremes, or will anchoring trigger profit-taking?
Updated: 09/08/2026, 02:46 PM
What could change this?
👥 What the crowd believes
"MNKD could be 48% undervalued following its Afrezza and pipeline narrative"
"Three revenue streams continue to feed modest growth for MannKind Corporation"
"Wells Fargo lowers price target to $13"
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 98/100
🔴 Weakest match
Jesse Livermore — 18/100
🗣️ Why do they disagree?
The stark divide in verdicts for MNKD reflects deep contrasts in how these methodologies weigh risk, valuation, and market psychology. Edgar Lawrence Smith’s high score suggests he sees this as a long-term, patient ‘buy and hold’ opportunity, likely due to its perceived stability or growth potential over time. In contrast, the majority of investors—especially those like Benjamin Graham, Howard Marks, and Jack Schwager—flag it as risky or overvalued, with scores as low as 18, emphasizing either weak fundamentals, speculative bubbles, or late-cycle warning signs. Meanwhile, Peter Lynch and the efficient-market camp see mixed signals, hinting at growth already priced in or insufficient evidence to justify active picking over passive indexing. The spectrum from Smith’s bullishness to Veblen’s skepticism (scoring just 21) underscores whether the stock aligns with disciplined, value-driven investing or speculative, crowd-driven trends.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 98
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 91
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 77
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 70
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 65
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 53
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 52
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 47
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 45
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 45
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 40%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 40
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 31
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 28
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 18
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 285 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
92.3%
Operating Margin
11.1%
Net Margin
1.7%
EBITDA Margin
14.6%
ROE
-11.5%
ROA
0.7%
ROIC
—
EPS
$0.02
Cash
$74.88M
Total Debt
$354.64M
Current Ratio
1.70
Debt/Equity
-6.95
How is Fair Value calculated? →
Current Price
$3.34
Estimated Fair Value (DCF)
$0.22
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-93.4%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $17.11M | $15.70M |
| 2 | 19.4% | $20.43M | $17.19M |
| 3 | 13.8% | $23.24M | $17.94M |
| 4 | 8.1% | $25.12M | $17.80M |
| 5 | 2.5% | $25.75M | $16.74M |
Base FCF (last actual year)
$13.69M
Terminal Value
$406.08M
Present Value of Terminal Value
$263.92M
Enterprise Value
$349.29M
Net Debt
$279.76M
Equity Value
$69.53M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
-$0.16
Tangible Book Value per Share (Tangible NAV)
-$0.39
Sentiment based on basic keywords (not AI) — 6 positive, 11 neutral, 3 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Benzinga · 11.9.2026
Stocktwits · 9.9.2026
Yahoo · 9.9.2026
Benzinga · 9.9.2026
MT Newswires · 9.9.2026
GlobeNewswire · 9.9.2026
Yahoo · 9.9.2026
Benzinga · 9.9.2026
Yahoo · 2.9.2026
GlobeNewswire · 2.9.2026
Yahoo · 29.8.2026
Simply Wall St. · 29.8.2026
Yahoo · 28.8.2026
Zacks · 28.8.2026
Benzinga · 21.8.2026
SeekingAlpha · 13.8.2026
MT Newswires · 6.8.2026
SeekingAlpha · 6.8.2026
MannKind Corporation (MNKD) currently has a StockIQ AI score of 41/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
MNKD currently scores 41/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, MNKD's estimated fair value is $0.22, which is 93.4% below the current price of $3.34. This is one valuation model among several signals in the fair-value category, not a price target.
MNKD's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 22.2%; Operating margin is stable or improving over time; Debt/equity: -6.95.
Based on the real signals StockIQ computed: Estimated fair value: $0.22 vs. price $3.34 (-93.4%); ATR: 5.4% of price; Calmar: -0.09 (3y annualized return -6.1% / max drawdown 69.4%).
StockIQ has no recorded dividend payment history for MNKD.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 7 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Binder Steven B. | Open Market Sale | 10.9.2026 | 752,309 | -33,558 | $3.81 |
| Binder Steven B. | Open Market Sale | 7.8.2026 | 39,051 | -39,051 | $4.06 |
| Binder Steven B. | Open Market Sale | 7.8.2026 | 785,867 | -39,051 | $4.06 |
| Binder Steven B. | Open Market Sale | 17.7.2026 | 52,485 | -52,485 | $4.06 |
| Thomson David | Open Market Sale | 17.7.2026 | 24,109 | -24,109 | $4.05 |
| Thomson David | Open Market Sale | 17.7.2026 | 797,554 | -24,109 | $4.05 |
| Binder Steven B. | Open Market Sale | 17.7.2026 | 824,918 | -52,485 | $4.06 |
| Binder Steven B. | Exercise of Derivative Securities | 15.7.2026 | 93,790 | -93,790 | — |
| Binder Steven B. | Tax Withholding in Shares | 15.7.2026 | 4,634 | -4,634 | $4.09 |
| Binder Steven B. | Tax Withholding in Shares | 15.7.2026 | 15,688 | -15,688 | $4.09 |
| Binder Steven B. | Tax Withholding in Shares | 15.7.2026 | 4,073 | -4,073 | $4.09 |
| Thomson David | Tax Withholding in Shares | 15.7.2026 | 12,662 | -12,662 | $4.09 |
| Thomson David | Tax Withholding in Shares | 15.7.2026 | 16,378 | -16,378 | $4.09 |
| Thomson David | Exercise of Derivative Securities | 15.7.2026 | 93,790 | -93,790 | — |
| Castagna Michael | Exercise of Derivative Securities | 15.7.2026 | 350,260 | -350,260 | — |
| Thomson David | Tax Withholding in Shares | 15.7.2026 | 17,754 | -17,754 | $4.09 |
| Singh Sanjay R | Tax Withholding in Shares | 15.7.2026 | 10,079 | -10,079 | $4.09 |
| Marasco Dominic | Tax Withholding in Shares | 15.7.2026 | 3,623 | -3,623 | $4.09 |
| Tross Stuart A | Tax Withholding in Shares | 15.7.2026 | 33,652 | -33,652 | $4.09 |
| Thomson David | Exercise of Derivative Securities | 15.7.2026 | 93,790 | +93,790 | — |
| Binder Steven B. | Exercise of Derivative Securities | 15.7.2026 | 93,790 | +93,790 | — |
| Castagna Michael | Tax Withholding in Shares | 15.7.2026 | 58,904 | -58,904 | $4.09 |
| Thomson David | Tax Withholding in Shares | 15.7.2026 | 51,632 | -51,632 | $4.09 |
| Tross Stuart A | Exercise of Derivative Securities | 15.7.2026 | 93,790 | +93,790 | — |
| Singh Sanjay R | Tax Withholding in Shares | 15.7.2026 | 5,372 | -5,372 | $4.09 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
29,398,550 shares short as of 2026-09-15 · vs. 26,554,857 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
39.1% of trading volume this week was short selling, vs. 59.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology